Advertisement
Screener

Dianthus Therapeutics, Inc. /DE/ (DNTH) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Dianthus Therapeutics, Inc. /DE/ Comprehensive Income

Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Comprehensive Income of -$51.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04

  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$51.77M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$41.90M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$64.11M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$36.70M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$161.95M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$84.91M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$43.35M.
  • Dianthus Therapeutics, Inc. /DE/ comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$28.64M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$51.77M
10-Q · filed 2026-08-04
-$93.67M
10-Q · filed 2026-08-04
-$157.77M
derived: sum of 3 quarters · filed 2026-08-04
-$194.47M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$41.90M
10-Q · filed 2026-05-05
-$106.00M
derived: sum of 2 quarters · filed 2026-05-05
-$142.70M
derived: sum of 3 quarters · filed 2026-05-05
-$174.50M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$64.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$100.81M
derived: sum of 2 quarters · filed 2026-03-09
-$132.61M
derived: sum of 3 quarters · filed 2026-08-04
-$161.95M
10-K · filed 2026-03-09
2025-09-30-$36.70M
10-Q · filed 2025-11-05
-$68.50M
derived: sum of 2 quarters · filed 2026-08-04
-$97.85M
10-Q · filed 2025-11-05
-$126.86M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$31.80M
10-Q · filed 2026-08-04
-$61.15M
10-Q · filed 2026-08-04
-$90.16M
derived: sum of 3 quarters · filed 2026-08-04
-$114.62M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$29.35M
10-Q · filed 2026-05-05
-$58.36M
derived: sum of 2 quarters · filed 2026-05-05
-$82.82M
derived: sum of 3 quarters · filed 2026-05-05
-$100.44M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$29.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$53.47M
derived: sum of 2 quarters · filed 2026-03-09
-$71.09M
derived: sum of 3 quarters · filed 2026-03-09
-$84.91M
10-K · filed 2026-03-09
2024-09-30-$24.46M
10-Q · filed 2025-11-05
-$42.07M
derived: sum of 2 quarters · filed 2025-11-05
-$55.90M
10-Q · filed 2025-11-05
-$66.41M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30-$17.62M
10-Q · filed 2025-08-07
-$31.44M
10-Q · filed 2025-08-07
-$41.95M
derived: sum of 3 quarters · filed 2025-08-07
-$56.70M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$13.82M
10-Q · filed 2025-05-12
-$24.33M
derived: sum of 2 quarters · filed 2025-05-12
-$39.08M
derived: sum of 3 quarters · filed 2025-05-12
-$50.18M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$10.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$25.26M
derived: sum of 2 quarters · filed 2025-03-11
-$36.36M
derived: sum of 3 quarters · filed 2025-03-11
-$43.35M
10-K · filed 2025-03-11
2023-09-30-$14.75M
10-Q · filed 2024-11-07
-$25.85M
derived: sum of 2 quarters · filed 2024-11-07
-$32.84M
10-Q · filed 2024-11-07
-$42.96M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$11.10M
10-Q · filed 2024-08-08
-$3.27M
10-Q · filed 2023-08-03
-$18.09M
10-Q · filed 2024-08-08
-$32.28M
10-Q · filed 2023-08-03
-$28.21M
derived: sum of 3 quarters · filed 2024-08-08
-$36.15M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$6.99M
10-Q · filed 2024-05-09
-$29.00M
10-Q · filed 2023-05-15
-$17.11M
derived: sum of 2 quarters · filed 2024-05-09
-$25.05M
derived: sum of 3 quarters · filed 2024-05-09
-$42.45M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$10.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$18.06M
derived: sum of 2 quarters · filed 2024-03-21
-$35.47M
derived: sum of 3 quarters · filed 2024-03-21
-$28.64M
10-K · filed 2024-03-21
-$76.61M
10-K · filed 2023-03-23
2022-09-30-$7.93M
10-Q · filed 2023-11-09
-$15.92M
10-Q · filed 2022-11-03
-$25.34M
derived: sum of 2 quarters · filed 2023-11-09
-$18.51M
10-Q · filed 2023-11-09
-$56.72M
10-Q · filed 2022-11-03
-$10.02M
derived: sum of 4 quarters · filed 2023-12-21
2022-06-30-$17.40M
10-Q · filed 2023-08-03
-$40.79M
10-Q · filed 2023-08-03
-$2.08M
derived: sum of 3 quarters · filed 2023-12-21
-$19.51M
derived: sum of 4 quarters · filed 2023-12-21
2022-03-31-$23.39M
10-Q · filed 2023-05-15
$15.32M
derived: sum of 2 quarters · filed 2023-12-21
-$2.11M
derived: sum of 3 quarters · filed 2023-12-21
-$19.04M
derived: sum of 4 quarters · filed 2023-12-21
2021-12-31$38.71M
derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21
$21.28M
derived: sum of 2 quarters · filed 2023-12-21
$4.35M
derived: sum of 3 quarters · filed 2023-12-21
-$13.11M
8-K · filed 2023-12-21
-$71.14M
10-K · filed 2022-03-08
2021-09-30-$17.43M
10-Q · filed 2022-11-03
-$34.36M
derived: sum of 2 quarters · filed 2022-11-03
-$51.82M
10-Q · filed 2022-11-03
-$70.05M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30-$16.93M
10-Q · filed 2022-08-04
-$34.39M
10-Q · filed 2022-08-04
-$52.62M
derived: sum of 3 quarters · filed 2022-08-04
-$70.41M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$17.46M
10-Q · filed 2022-05-16
-$35.69M
derived: sum of 2 quarters · filed 2022-05-16
-$53.48M
derived: sum of 3 quarters · filed 2022-05-16
-$72.77M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$18.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
-$36.02M
derived: sum of 2 quarters · filed 2022-03-08
-$55.31M
derived: sum of 3 quarters · filed 2022-03-08
-$74.97M
10-K · filed 2022-03-08
2020-09-30-$17.79M
10-Q · filed 2021-11-04
-$37.08M
derived: sum of 2 quarters · filed 2021-11-04
-$56.74M
10-Q · filed 2021-11-04
-$80.05M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$19.29M
10-Q · filed 2021-08-05
-$38.95M
10-Q · filed 2021-08-05
-$62.26M
derived: sum of 3 quarters · filed 2021-08-05
-$83.30M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$19.66M
10-Q · filed 2021-05-06
-$42.97M
derived: sum of 2 quarters · filed 2021-05-06
-$64.01M
derived: sum of 3 quarters · filed 2021-05-06
-$81.62M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$23.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03
-$44.36M
derived: sum of 2 quarters · filed 2021-03-03
-$61.97M
derived: sum of 3 quarters · filed 2021-03-03
-$76.75M
10-K · filed 2021-03-03
2019-09-30-$21.05M
10-Q · filed 2020-11-05
-$38.66M
derived: sum of 2 quarters · filed 2020-11-05
-$53.44M
10-Q · filed 2020-11-05
-$70.13M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$17.61M
10-Q · filed 2020-08-06
-$32.40M
10-Q · filed 2020-08-06
-$49.08M
derived: sum of 3 quarters · filed 2020-08-06
-$65.10M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$14.79M
10-Q · filed 2020-05-07
-$31.47M
derived: sum of 2 quarters · filed 2020-05-07
-$47.49M
derived: sum of 3 quarters · filed 2020-05-07
-$61.15M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$16.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
-$32.70M
derived: sum of 2 quarters · filed 2020-03-03
-$46.36M
derived: sum of 3 quarters · filed 2020-03-03
-$57.52M
10-K · filed 2020-03-03
2018-09-30-$16.02M
10-Q · filed 2019-11-13
-$29.68M
derived: sum of 2 quarters · filed 2019-11-13
-$40.84M
10-Q · filed 2019-11-13
-$48.87M
derived: sum of 4 quarters · filed 2020-03-03
2018-06-30-$13.66M
10-Q · filed 2019-08-08
-$24.82M
10-Q · filed 2019-08-08
-$32.86M
derived: sum of 3 quarters · filed 2020-03-03
-$39.77M
derived: sum of 4 quarters · filed 2020-03-03
2018-03-31-$11.16M
10-Q · filed 2019-05-09
-$19.20M
derived: sum of 2 quarters · filed 2020-03-03
-$26.11M
derived: sum of 3 quarters · filed 2020-03-03
-$41.84M
derived: sum of 4 quarters · filed 2020-03-03
2017-12-31-$8.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
-$14.95M
derived: sum of 2 quarters · filed 2020-03-03
-$30.68M
derived: sum of 3 quarters · filed 2020-03-03
-$35.49M
10-K · filed 2020-03-03
2017-09-30-$6.91M
10-Q · filed 2018-11-08
-$22.64M
derived: sum of 2 quarters · filed 2018-11-08
-$27.45M
10-Q · filed 2018-11-08
2017-06-30-$15.73M
10-Q · filed 2018-08-09
-$20.54M
10-Q · filed 2018-08-09
2016-12-31-$9.43M
10-K · filed 2019-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51